Assessing lung blood pressure in heart failure patients
Hemodynamic Testing Strategies to Assess Pulmonary Hypertension and Right Ventricular Function in Heart Failure Patients
Mount Sinai Hospital, Canada · NCT05672719
This study is trying to see how lung blood pressure affects heart failure patients to better predict their recovery after treatments like heart transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 74 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Mount Sinai Hospital, Canada (other) |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05672719 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate heart function and pulmonary hypertension in patients with heart failure. It focuses on predicting complications after treatments such as heart transplants and left ventricular assist devices. The study involves a prospective cohort of patients with reduced ejection fraction who are referred for right heart catheterization as part of their assessment for advanced heart failure therapies. By analyzing the data collected, researchers hope to improve predictive capabilities for patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with heart failure and reduced ejection fraction referred for right heart catheterization.
Not a fit: Patients with severe valvular disease, recent acute coronary syndrome, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict complications in heart failure patients, leading to better treatment decisions.
How similar studies have performed: Other studies have shown promise in using hemodynamic testing for similar patient populations, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults age 18 years or older * Heart failure with reduced ejection fraction (\<40%) * referred for RHC at our centre for evaluation of candidacy for advanced HF therapies. Exclusion Criteria: Severe valvular or complex congenital heart disease Short-term mechanical circulatory support for progressive cardiogenic shock (e.g. extracorporeal membrane oxygenation) Acute coronary syndrome or revascularization occurred within 7 days prior to the RHC. Pregnant or breast-feeding Known hypersensitivity to sodium nitroprusside Advanced liver dysfunction Reduced capacity or inability to provide informed consent
Where this trial is running
Toronto, Ontario
- Mount Sinai Hospital — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Susanna Mak, MD PhD — University of Toronto
- Study coordinator: Susanna Mak, MD PhD
- Email: susanna.mak@sinaihealth.ca
- Phone: 4165864800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Heart Failure